Menumenu
  • slide

    Rapid access to our in-house patient-centric Database Network

  • slide

    An experienced sparring partner for your European healthcare questions

  • slide

    Dedicated to research real-life healthcare for the benefit of patients

  • News

    Cohort profile: the PHARMO Perinatal Research Network

    Congratulations to our colleague @Eline Houben, whose publication "Cohort profile: the PHARMO Perinatal Research Network (PPRN) in the Netherlands: a population-based mother–child linked cohort" has made it into the top 10 most read publications in...

    PHARMO Magazine (May 2021)

    We are proud to hereby offer you our latest edition of our PHARMO magazine. In this online magazine you can, amongst others, read about our unique linkage to the Netherlands Cancer Registry (NCR), the newly developed COVID-19 algorithm that predic...

    Wetenschappelijk jaarverslag 2020

    Het jaar 2020 was voor iedereen een bijzonder jaar. Termen als lockdown en quarantaine beheersten ons leven en iedereen ging thuiswerken. Maar de studies en overige activiteiten van het PHARMO Instituut gingen onverminderd door en ondanks het bijzond...

  • Events

  • Vacancy

  • icon

    What we do

    As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  • icon

    What we have

    PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

Publications

  • Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

    Read more

  • No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

    Read more

  • Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

    Read more

  • The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

    Read more